Use of Pregabalin for attenuation of hemodymanic response to laryngoscopy and intubation in treated hypertensive patients

Use of Pregabalin for attenuation of hemodymanic response to laryngoscopy and intubation in treated hypertensive patients - Use of Pregabalin for attenuation of hemodymanic response to laryngoscopy and intubation in treated hypertensive patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037103

Enrollment

Registered

2019-06-19

Start date

2018-03-05

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

premptive pregabalin in hypertensive patient

Interventions

A thorough pre-anaesthetic assessment and investigations will be performed before patient selection. An informed written consent will be taken in all the patients. All the patients will be pre-medicat

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Scheduled for elective surgery under general anesthesia . 2. All patients with controlled hypertension. 3. All patients of ASA physical status II. 4. Patient aged 30-70 years.

Exclusion criteria

Exclusion criteria: 1. Unwilling patients. 2. Patients with ASA grade III or higher. 3. Pre-existing cardiac disease, asthma, and severe renal or hepatic dysfunction. 4. Anticipated difficult intubation. 5. Patients with morbid obesity. 6. History of taking antidepressants drugs.

Design outcomes

Primary

Measure	Time frame
Response of preemptive Pregabalin in attenuating the hemodynamic response to laryngoscopy and intubation in treated hypertensive patients.	—

Secondary

Measure	Time frame
1. pre-operative anxiety level 2. heart rate 3. systolic and diastolic pressure. 4. mean arterial pressure. 5. side effects	—

Countries

Asia(except Japan)

Contacts

Public ContactPuja Thapa

Nepalese Army Institute of Health Sciences Bagmati

thapa_puza@yahoo.com009779851152449

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026